Mountain Crest Acquisition Corp. II Common Stock (MCAD)

Etorro trading 970x250

About Mountain Crest Acquisition Corp. II Common Stock

Mountain Crest Acquisition Corp. II, a blank check company, intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York. Address: 311 West 43rd Street, New York, NY, United States, 10036

Mountain Crest Acquisition Corp. II Common Stock News and around…

Latest news about Mountain Crest Acquisition Corp. II Common Stock (MCAD) common stock and company :

Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021
13 Oct, 2021 Yahoo! Finance

NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD’s registration statement on Form S-4 (File No. 333-255493) relating to the previously an

Moore Kuehn Encourages EBMT, ESBK, BCML, and MCAD Investors to Contact Law Firm
07 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Eagle Bancorp Montana, Inc. (NASDAQ GM: EBMT) Eagle Bancorp has agreed to merge with First Commu

Better Therapeutics to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021
10 Sep, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference, which is being held virtually on September 14-15, 2021.

Better Therapeutics to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021
10 Sep, 2021 Yahoo! Finance

SAN FRANCISCO, September 10, 2021--Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference, which is being held virtually on September 14-15, 2021.

Better Therapeutics Highlights Recent Progress and Updates Outlook Through 2022
09 Sep, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress since announcing its intention to merge with Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (“Mountain Crest II”). The merger and concurrent PIPE and debt financings are expected to close in October.

Better Therapeutics Secures $50 Million Debt Facility From Hercules Capital
25 Aug, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it has secured a loan facility for up to $50 million from Hercules Capital, Inc. (NYSE: HTGC).

Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network
24 Aug, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network (“Catalyst”), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes. Catalyst joins the Colorado Prevention Center in the study of BT-001, an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Better Therapeutics, Inc. to Present at the Canaccord Genuity’s 41st Annual Growth Conference
04 Aug, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

The Week In SPAC News - Sunday, Aug. 1
01 Aug, 2021 FinancialContent

In SPAC news this week, Allego announced a business combination with Spartan Acquisition Corp. III, while Swvl Inc. is said to be near a deal to go public via a merger with Queen's Gambit Growth Capital.

Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
29 Jul, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz Medical Campus, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes. BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Better Therapeutics to Participate in Cowen 6th Annual FutureHealth Conference
14 Jun, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel discussions at the Cowen 6th Annual FutureHealth Conference on June 17, 2021.

Lifshitz Law Firm, P.C. Announces Investigation of BMTC, WSFS, CAHC, CBAN, SCSG, INDB, EBSB, INSW, DSSI, MCAD, VER and O
04 May, 2021 Yahoo! Finance

Bryn Mawr Bank Corporation (NASDAQ: BMTC) - WSFS Financial Corp. (NASDAQGS: WSFS)

INVESTIGATION ALERT: Halper Sadeh LLP Investigates MCAD, CAHC, ROT, MUDS, LATN; Shareholders are Encouraged to Contact the Firm
29 Apr, 2021 Yahoo! Finance

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Mountain Crest Acquisition Corp. II Merger
27 Apr, 2021 FinancialContent
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Mountain Crest Acquisition Corp. II - MCAD
24 Apr, 2021 Yahoo! Finance

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Mountain Crest Acquisition Corp. II ("MCAD" or the "Company") (MCAD) relating to its proposed merger with Better Therapeutics. Under the terms of the agreement, MCAD will acquire Better through a reverse merger, with Better emerging as a publicly traded company.

Better Therapeutics Commences Pivotal Study of Prescription Digital Therapeutic for the Treatment of Type 2 Diabetes
22 Apr, 2021 FinancialContent

Better Therapeutics, Inc., (“Better Therapeutics”) a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the enrollment of the first patient in its pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of type 2 diabetes. The study began screening patients in February and the first of those patients have now completed the run-in period. BT-001 is an FDA-regulated, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes. The study adopts a fully virtual model and is actively recruiting patients across five states: Texas, Illinois, Florida, California and New York.

Better Therapeutics Appoints Dr. Risa Lavizzo-Mourey to its Board of Directors
20 Apr, 2021 FinancialContent

Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair.

Better Therapeutics Launches Real World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
14 Apr, 2021 FinancialContent

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the commencement of a real-world evidence study with Steward Health Care to evaluate the long-term effectiveness and cost of care impact associated with the use of BT-001 for the treatment of type 2 diabetes. BT-001 is an investigational, prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes.

Moore Kuehn Encourages MUDS, ROT, CAHC, and MCAD Investors to Contact Law Firm
12 Apr, 2021 FinancialContent
SPACs Attack Weekly Recap: 6 Deals, Rumors And Headline News
11 Apr, 2021 FinancialContent

It was another busy week for the SPAC market with numerous deal announcements and rumored deals. Benzinga's "SPACs ...

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Mountain Crest Acquisition Corp. II (Nasdaq - MCAD)
07 Apr, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / April 7, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Mountain Crest Acquisition Corp. II ("Mountain Crest" or the "Company") (Nasdaq:MCAD) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Mountain Crest, a special purpose acquisition company, will combine with Better Therapeutics, Inc.

Better Therapeutics To Go Public Via Mountain Crest SPAC Deal
07 Apr, 2021 FinancialContent

Better Therapeutics Inc, a company developing prescription-only smartphone-based treatments for Type 2 diabetes and high blood ...

Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II
07 Apr, 2021 FinancialContent

Better Therapeutics, Inc. a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, will go public, raising up to $113 million to advance its robust pipeline of products to treat cardiometabolic diseases, conditions which cost the U.S. healthcare system almost $500 billion each year. Better Therapeutics has entered into a definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD; “Mountain Crest II”), a publicly traded special purpose acquisition corporation or SPAC. The transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company. Upon completion of the transaction, which is anticipated in the summer 2021, the combined company will operate as Better Therapeutics and securities are expected to be listed on Nasdaq under the symbol “BTTX.”

Mountain Crest Acquisition Corp. II Announces that Common Stock and Rights to Commence Separate Trading on or about March 17, 2021
15 Mar, 2021 FinancialContent

Mountain Crest Acquisition Corp. II Common Stock (MCAD) is a NASDAQ Common Stock listed in , ,

970x250